Tellimer logo
Search icon
Equity Analysis /
United States of America

US : 89bio, Inc. - ETNB | 1Q21 Update: 2Q21 Phase 2b NASH Study Initiation with Histology Primary Endpoints

    Contributors
    Ryan Deschner
    Timur Ivannikov
    CGS-CIMB
    13 May 2021
    Published by

    Watchlist

    Tellimer | Start Following

    Start following your markets today

    Follow your key analysts, markets and more so they appear here in your Watchlist - allowing you to keep an eye on the latest updates.